China
Africa
Explore chapters and articles related to this topic
Colorectal Cancer
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Since the pivotal MOSAIC trial, no further progress in improving overall survival in unselected Dukes’ B and C patients has been made. The addition of a third agent to FOLFOX, either cetuximab or bevacizumab, was not superior. Neither was their equivalence when switching from oxaliplatin to irinotecan. However, approaches to reduce treatment toxicity and improve the quality of life in patients by giving shorter-duration FOLFOX or CAPOX chemotherapy have been successfully tested. In the United Kingdom, the SCOT trial, which was also part of a larger global initiative (the IDEA collaboration), demonstrates that 3 months duration versus the standard 6 months, in most subsets of patients, is a non-inferior approach with a significant reduction in neuropathy risk, improved quality of life, and improved health economics.180
HPB Surgery
Published in Tjun Tang, Elizabeth O'Riordan, Stewart Walsh, Cracking the Intercollegiate General Surgery FRCS Viva, 2020
London Lucien Ooi Peng Jin, Teo Jin Yao
Is there a role for neoadjuvant therapy in the management of pancreatic cancer?In situations where the pancreatic head lesion is of borderline resectability, i.e. an R0 resection may not be achievable, then neoadjuvant chemotherapy or chemoradiation may be a consideration to increase the operability for R0 resection. The common chemotherapy agent is gemcitabine although FOLFOX is increasingly being used as an option.
Gastrointestinal cancer
Published in Peter Hoskin, Peter Ostler, Clinical Oncology, 2020
Chemotherapy using 5FU and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (XELOX) is recommended for all patients with stage III cancers. This may also be offered to some high risk stage II cancers, e.g. those with T4 cancers, presentation with obstruction or perforation, venous invasion, inadequate lymph node sampling.
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Published in Expert Opinion on Investigational Drugs, 2021
Gabriella Aitcheson, Amit Mahipal, Binu V John
For those who fail first-line chemotherapy with gem-cis, the phase III ABC-06 trial presented the chemotherapy combination of folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) as a potential standard second-line therapy. [14] Patients who had been diagnosed with advanced BTC whose disease progressed while taking gem-cis were assigned to receive either active symptom control or active symptom control with FOLFOX. Approximately 44% of the patients were noted to have an intrahepatic primary tumor site. When comparing those who underwent FOLFOX in addition to active symptom control and those who only underwent active symptom control, 6-month and 12-month survival were notable with 50.6% vs 35.5% and 25.9% vs 11.4%. MOS did not denote a significant difference with 6.2 months vs 5.3 months. Those most common adverse events were fatigue and neutropenia, occurring more prominently in the FOLFOX group with 59% versus 39%. Given the lacking landscape of efficacious second-line treatments, the addition of new therapeutic options is anxiously awaited.
Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection
Published in OncoImmunology, 2020
Qiu-Zhong Pan, Jing-Jing Zhao, Chao-Pin Yang, Yu-Qing Zhou, Jun-Zhong Lin, Yan Tang, Jia-Mei Gu, Qi-Jing Wang, Yong-Qiang Li, Jia He, Shi-Ping Chen, Meng-Jia Song, Yue Huang, Jie-Ying Yang, De-Sheng Weng, Jian-Chuan Xia
All patients underwent completion resection. Following surgery, all patients in the control and CIK groups received adjuvant chemotherapy with FOLFOX (bolus and infused fluorouracil with oxaliplatin), CAPOX (oxaliplatin and capecitabine), or single-agent capecitabine regimen. For patients receiving FOLFOX, treatment was given every 2 weeks with the intention of delivering twelve cycles to patients assigned 24 weeks of therapy. For patients receiving CAPOX or single-agent capecitabine, treatment was given every 3 weeks with an intention of delivering eight cycles to patients assigned 24 weeks of therapy. The duration of chemotherapy included neoadjuvant and adjuvant treatment stage (Supplementary Table S1). Dose reductions or treatment delays were calculated according to the treatment- related adverse events, which were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0.
The Adjuvant Effect of Squalene, an Active Ingredient of Functional Foods, on Doxorubicin-Treated Allograft Mice
Published in Nutrition and Cancer, 2019
Hari Narayan Bhilwade, Naoto Tatewaki, Tetsuya Konishi, Miyako Nishida, Takahiro Eitsuka, Hironobu Yasui, Osamu Inanami, Osamu Handa, Yuji Naito, Nobuo Ikekawa, Hiroshi Nishida
One of the chemotherapy combinations commonly used in the treatment of colon cancer is FOLFOX. This chemotherapy is given to shrink tumors and alleviate symptoms for a colon cancer patient. FOLFOX is a combination therapy using three drugs, leucovorin calcium (folinic acid), fluorouracil (5-FU) and oxaliplatin. Each drug enhances the therapeutic effect by suppressing the proliferation of cancer cells depending on different mechanism. As a result, extremely complicated DNA damage response is caused in cancer cells. On the other hand, DOX, a single chemotherapy agent, mainly induces DNA double strand breaks (DSB) and it is commonly used for treatment of colon cancer (43–46). In our previous study, we demonstrated that SQ enhances cancer cell death due to DNA damage accompanied with DSB (47). Therefore, here we have used DOX as a DSB-inducing chemotherapeutic agent to evaluate the possible beneficial effects of SQ in tumor-bearing mice. The present study describes the analgesic and anti-inflammatory activity of SQ and also highlights its beneficial effects in terms of improving the outcome of DOX therapy in tumor-being mice.